false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Autosom ...
ADPKD Diagnostic Criteria, Risk Stratification, an ...
ADPKD Diagnostic Criteria, Risk Stratification, and Prognosis Prediction
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Fawad Chabib reviewed diagnosis and prognosis in autosomal dominant polycystic kidney disease (ADPKD), emphasizing its wide variation in severity, genetic causes, and effects beyond the kidneys. Although PKD1 and PKD2 account for most cases, newer, less common genes can produce milder or distinctive disease patterns, making genetic testing increasingly useful.<br /><br />For people with an affected relative, ultrasound is generally the first screening test; MRI or CT and genetic testing can clarify uncertain cases. Imaging and genetic results also help distinguish ADPKD from age-related cysts and other cystic or kidney diseases. Accurate exclusion is especially important when a potential kidney donor is being assessed.<br /><br />Prognosis combines family history, genotype, kidney function over time, and imaging. Mayo Imaging Class, based on height-adjusted total kidney volume and age, is a practical tool for typical PKD1/PKD2 disease, but should not be applied to certain rarer genetic forms. Other promising indicators—including copeptin, bicarbonate, renal blood flow, and protein biomarkers—may improve predictions, though most are not yet routine clinical tools.<br /><br />Chabib called for larger, collaborative studies to make individualized predictions more reliable, develop better trial endpoints, and ensure patients can access and enroll in emerging treatment studies.
Asset Caption
Fouad T. Chebib, MD, FASN
Meta Tag
Speaker
Fouad Chebib
Keywords
autosomal dominant polycystic kidney disease
ADPKD
PKD1
PKD2
genetic testing
ultrasound screening
Mayo Imaging Class
prognosis
kidney donor evaluation
×
Please select your language
1
English